Limits...
Environmental factors preceding aβ40 monomer to oligomers and the detection of oligomers in Alzheimer's disease patient serum.

Matsunaga Y, Suenaga M - J Amino Acids (2012)

Bottom Line: We also suggest a new idea to detect Aβ40 oligomers with anti-Aβ40 monoclonal antibody using enzyme-linked immunosorbent assay.This method involves the different sensitivity of the thermal shifts between Aβ40 monomer and the oligomers.The idea is useful for the diagnostics of Alzheimer's disease to detect Aβ40 oligomers in the serum from the patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Medical Pharmacology, Faculty of Pharmaceutical Sciences, Tokushima Bunri University, Yamashiro-cho, Tokushima 770-8514, Japan.

ABSTRACT
We present here environmental factors including pH shifts, temperature, and metal ions surrounding Aβ40 monomer to precede the oligomers. We also suggest a new idea to detect Aβ40 oligomers with anti-Aβ40 monoclonal antibody using enzyme-linked immunosorbent assay. This method involves the different sensitivity of the thermal shifts between Aβ40 monomer and the oligomers. The idea is useful for the diagnostics of Alzheimer's disease to detect Aβ40 oligomers in the serum from the patients.

No MeSH data available.


Related in: MedlinePlus

Identification of response of temperature-modified serum of patients with Alzheimer's disease [14]. According to the criteria of National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders, AD patients were enrolled, and the patients were classified into two groups of mild AD and severe AD with age match. MMSE score 1–9 was as severe AD and the score of 10–22 was as mild AD. Sera from two AD groups were tested for their reactivity against 4G8 with ELISA. (a) The absorbance in the severe AD was lower than that of the mild AD though the temperatures and the signals from mild AD were almost constant; however, the significant lower signal was observed in severe AD at 40°C (P < 0.02) and 41°C (P < 0.05). The signals from Aβ40 peptide as a control showed decrease as the temperature increase in a temperature-dependent manner. (b) The minimum/maximum optical density ratio of each patient's serum was calculated and obtained the average of ratios for severe and mild AD. The ratio value for patients with severe AD (0.43 ± 0.05) was significantly (P < 0.001) lower than that for patients with mild AD (0.69 ± 0.01). The average min/max optical density value for the synthetic Aβ1–40 peptide, used as a control, was 0.72 ± 0.02.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3306785&req=5

fig5: Identification of response of temperature-modified serum of patients with Alzheimer's disease [14]. According to the criteria of National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders, AD patients were enrolled, and the patients were classified into two groups of mild AD and severe AD with age match. MMSE score 1–9 was as severe AD and the score of 10–22 was as mild AD. Sera from two AD groups were tested for their reactivity against 4G8 with ELISA. (a) The absorbance in the severe AD was lower than that of the mild AD though the temperatures and the signals from mild AD were almost constant; however, the significant lower signal was observed in severe AD at 40°C (P < 0.02) and 41°C (P < 0.05). The signals from Aβ40 peptide as a control showed decrease as the temperature increase in a temperature-dependent manner. (b) The minimum/maximum optical density ratio of each patient's serum was calculated and obtained the average of ratios for severe and mild AD. The ratio value for patients with severe AD (0.43 ± 0.05) was significantly (P < 0.001) lower than that for patients with mild AD (0.69 ± 0.01). The average min/max optical density value for the synthetic Aβ1–40 peptide, used as a control, was 0.72 ± 0.02.

Mentions: The clinical phase of AD was determined with MMSE, and mild AD presents MMSE over 24 and severe AD presents MMSE below 9. We used the sera from patients diagnosed with mild AD and severe AD to detect the different reactivity pattern to specific antibodies targeting Aβ17–21(4G8 moAb). The reactivity patterns of sera to 4G8 at 36–42°C was determined by ELISA. The Aβ40 peptide as a control showed the reactivity pattern in a temperature-dependent manner, and the reactivity of sera from patients with severe AD was less than that of sera from patients with mild AD though the temperatures 36–41°C and the remarkable fall down at 41-42°C were shown in severe AD, however, with no difference at 42°C (Figure 5(a)). The severity of AD is associated with greater Aβ40 aggregation. We propose that the ratio of differences of signals with ELISA between 38°C and 40°C is useful to determine the severity of AD (Figure 5(b)). The present results may be of value in staging and following up of patients with AD.


Environmental factors preceding aβ40 monomer to oligomers and the detection of oligomers in Alzheimer's disease patient serum.

Matsunaga Y, Suenaga M - J Amino Acids (2012)

Identification of response of temperature-modified serum of patients with Alzheimer's disease [14]. According to the criteria of National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders, AD patients were enrolled, and the patients were classified into two groups of mild AD and severe AD with age match. MMSE score 1–9 was as severe AD and the score of 10–22 was as mild AD. Sera from two AD groups were tested for their reactivity against 4G8 with ELISA. (a) The absorbance in the severe AD was lower than that of the mild AD though the temperatures and the signals from mild AD were almost constant; however, the significant lower signal was observed in severe AD at 40°C (P < 0.02) and 41°C (P < 0.05). The signals from Aβ40 peptide as a control showed decrease as the temperature increase in a temperature-dependent manner. (b) The minimum/maximum optical density ratio of each patient's serum was calculated and obtained the average of ratios for severe and mild AD. The ratio value for patients with severe AD (0.43 ± 0.05) was significantly (P < 0.001) lower than that for patients with mild AD (0.69 ± 0.01). The average min/max optical density value for the synthetic Aβ1–40 peptide, used as a control, was 0.72 ± 0.02.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3306785&req=5

fig5: Identification of response of temperature-modified serum of patients with Alzheimer's disease [14]. According to the criteria of National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders, AD patients were enrolled, and the patients were classified into two groups of mild AD and severe AD with age match. MMSE score 1–9 was as severe AD and the score of 10–22 was as mild AD. Sera from two AD groups were tested for their reactivity against 4G8 with ELISA. (a) The absorbance in the severe AD was lower than that of the mild AD though the temperatures and the signals from mild AD were almost constant; however, the significant lower signal was observed in severe AD at 40°C (P < 0.02) and 41°C (P < 0.05). The signals from Aβ40 peptide as a control showed decrease as the temperature increase in a temperature-dependent manner. (b) The minimum/maximum optical density ratio of each patient's serum was calculated and obtained the average of ratios for severe and mild AD. The ratio value for patients with severe AD (0.43 ± 0.05) was significantly (P < 0.001) lower than that for patients with mild AD (0.69 ± 0.01). The average min/max optical density value for the synthetic Aβ1–40 peptide, used as a control, was 0.72 ± 0.02.
Mentions: The clinical phase of AD was determined with MMSE, and mild AD presents MMSE over 24 and severe AD presents MMSE below 9. We used the sera from patients diagnosed with mild AD and severe AD to detect the different reactivity pattern to specific antibodies targeting Aβ17–21(4G8 moAb). The reactivity patterns of sera to 4G8 at 36–42°C was determined by ELISA. The Aβ40 peptide as a control showed the reactivity pattern in a temperature-dependent manner, and the reactivity of sera from patients with severe AD was less than that of sera from patients with mild AD though the temperatures 36–41°C and the remarkable fall down at 41-42°C were shown in severe AD, however, with no difference at 42°C (Figure 5(a)). The severity of AD is associated with greater Aβ40 aggregation. We propose that the ratio of differences of signals with ELISA between 38°C and 40°C is useful to determine the severity of AD (Figure 5(b)). The present results may be of value in staging and following up of patients with AD.

Bottom Line: We also suggest a new idea to detect Aβ40 oligomers with anti-Aβ40 monoclonal antibody using enzyme-linked immunosorbent assay.This method involves the different sensitivity of the thermal shifts between Aβ40 monomer and the oligomers.The idea is useful for the diagnostics of Alzheimer's disease to detect Aβ40 oligomers in the serum from the patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Medical Pharmacology, Faculty of Pharmaceutical Sciences, Tokushima Bunri University, Yamashiro-cho, Tokushima 770-8514, Japan.

ABSTRACT
We present here environmental factors including pH shifts, temperature, and metal ions surrounding Aβ40 monomer to precede the oligomers. We also suggest a new idea to detect Aβ40 oligomers with anti-Aβ40 monoclonal antibody using enzyme-linked immunosorbent assay. This method involves the different sensitivity of the thermal shifts between Aβ40 monomer and the oligomers. The idea is useful for the diagnostics of Alzheimer's disease to detect Aβ40 oligomers in the serum from the patients.

No MeSH data available.


Related in: MedlinePlus